Jonathan Hepple

Ph D
Oncology
Clanotech
Sweden

Business Expert Oncology
Biography

Jonathan Hepple, Ph D, Venture investor in life science companies since 1998. Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Enobia Pharmaceuticals, GeminX Pharmaceuticals, Cytochroma, Forward Pharma and Zealand Pharmaceuticals. Also Partner at Seroba Kernel Life Sciences, a European venture firm, investing in biotech and medtech. Current board seats include Axelar AB, Clanotech AB, Covagen AG and Opsona Therapeutics.

Research Intrest

Jonathan Hepple, Ph D, Venture investor in life science companies since 1998. Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Enobia Pharmaceuticals, GeminX Pharmaceuticals, Cytochroma, Forward Pharma and Zealand Pharmaceuticals. Also Partner at Seroba Kernel Life Sciences, a European venture firm, investing in biotech and medtech. Current board seats include Axelar AB, Clanotech AB, Covagen AG and Opsona Therapeutics.